瑞舒伐他汀对CHD合并T2DM患者血糖和血管内皮功能及炎症因子水平的影响

Effects of rosuvastatin on blood glucose and vascular endothelial function and inflammatory factors in patients with CHD combined with T2DM

目的探讨瑞舒伐他汀在冠心病(CHD)合并2型糖尿病(T2DM)患者中的应用价值。方法选择2017年3月至2018年2月本院收治的CHD合并T2DM患者98例,并通过随机数字表法将其分为实验组和对照组,同时选择健康体检者49例作为正常组。实验组患者服用瑞舒伐他汀的药物治疗,对照组患者服用降脂通脉的药物治疗,正常组普通饮食,并分别比较和分析3组患者的血糖控制,血管内皮功能及炎症因子水平变化情况。结果与对照组相比,观察组治疗后的空腹血糖值(8.26±0.93)mmol/L和餐后2 h血糖值(9.11±1.02)mmol/L均有所降低;观察组治疗后的内皮素-1(50.75±6.18)pg/L水平明显降低,而一氧化氮(95.20±10.63)pg/L水平则明显提高(P<0.05);观察组治疗后的炎症因子白介素-1(0.23±0.13)μg/L和肿瘤坏死因子-α(39.95±5.01)μg/L水平均明显降低(P<0.05)。结论瑞舒伐他汀对于改善CHD合并T2DM患者血管内皮功能及调节炎症细胞因子水平均具有显著作用和优势。

Objective To probe into the the value of rosuvastatin in patients with coronary heart disease(CHD) combined with type 2 diabetes mellitus(T2 DM). Methods From March 2017 to February 2018, 98 patients with CHD and T2 DM were selected in our hospital. By random number table method, the patients were divided into experimental group and control group, and healthy physical examination subjects 49 cases were selected normal group. The patients in the experimental group were treated with rosuvastatin. The patients in the control group were treated with lipid lowering and dredge. The subjects in the normal group were given normal diet. The blood glucose control, vascular endothelial function and inflammatory factor of the patients in the three groups were compared and analyzed. Results Compared with the control group, the patients in the observation group, after treatment, the levels of fasting blood glucose were(8.26±0.93) mmol/L and the postprandial 2 h blood glucose were(9.11±1.02) mmol/L,which were decreased than before treatment;the patients in the observation group, after treatment, the level of endothelin-1 were(50.75±6.18) pg/L,which were decreased significantly than before treatment, while the level of nitric oxide were(95.20±10.63) pg/L, there were increased significantly(P<0.05);the patients in the observation group, after treatment, the levels of inflammatory factors interleukin-1 were(0.23±0.13)μg/L and tumor necrosis factor-α were(39.95±5.01)μg/L, there were decreased significantly(P<0.05). Conclusion Rosuvastatin has significant effect and advantage in improving vascular endothelial function and regulating inflammatory cytokine levels in patients with CHD and T2 DM.